对比增强立体定向活检(CESB):患者选择与实践考虑
本文为叙述性综述,介绍对比增强乳腺摄影(CEM)仅可见病灶的对比增强立体定向活检(CESB)技术,涵盖患者选择、操作流程、实践注意事项及现有文献概述,指出CESB自2020年起已商用,为传统MRI引导活检提供新替代。
要点
- CEM可显示低能图、超声或数字断层合成无对应表现的「CEM-only」病灶。
- 此类病灶传统上需MRI引导活检,CESB自2020年起成为商用替代方案。
- 本综述概述CESB患者选择、操作流程、实践注意事项及现有文献。
核心结论
- CESB为CEM-only病灶提供MRI引导活检之外的新替代方案,综述概述其患者选择、操作、注意事项及现有文献。
研究设计与样本
- 叙述性综述,回顾CEM及CESB相关文献,未报告系统检索范围与纳入文献数量。
关键影像表现/征象
- CEM可显示「CEM-only」病灶,即低能图、超声或数字断层合成无对应表现的对比增强区域。
- CEM诊断准确性媲美乳腺MRI,可作为乳腺MRI适应证的可行且可能具成本效益的替代。
临床应用与阅片要点
- 对CEM-only病灶,传统工作流程为行MRI引导活检,CESB提供新替代且自2020年起已商用。
- 综述涵盖CESB患者选择、操作流程及实践注意事项。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows 'CEM-only' lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.
引用
- Lobbes MBI, Theunissen J, Valentijn-Morsing A, et al. Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations. Eur J Radiol. 2024. PMID: 39366192. doi:10.1016/j.ejrad.2024.111768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。